Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
Allo-329, Cyclophophamide
Lupus Nephritis, Systemic Sclerosis, Systemic Lupus Erythematosus (With And Without Nephritis), Idiopathic Inflammatory Myopathy
Phase I
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Jul 08, 2025
―
Cyclophosphamide, Fludarabine, Allo-647, Allo-501A
Relapsed/Refractory Large B Cell Lymphoma
Phase II
Active Not Recruiting
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Dec 08, 2022
―
Cyclophosphamide, Fludarabine, Allo-647, Allo-605
Relapsed/Refractory Multiple Myeloma
Phase I/II
Terminated
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Aug 04, 2021
―
Cyclophosphamide, Fludarabine, Allo-647, Allo-316
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Phase I
Recruiting
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Jan 04, 2021
―
Cyclophosphamide, Fludarabine, Allo-647, Allo-501A
Relapsed Or Refractory Large B Cell Lymphoma, Relapsed Or Refractory Chronic Lymphocytic Leukemia, Relapsed Or Refractory Small Lymphocytic Lymphoma
Phase I/II
Active Not Recruiting
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
May 29, 2020
―
Cyclophosphamide, Nirogacestat, Fludarabine, Allo-715, Allo-647
Relapsed/Refractory Multiple Myeloma
Phase I
Active Not Recruiting
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
Sep 16, 2019
―
Cyclophosphamide, Fludarabine, Allo-647, Allo-501
Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Large B Cell Lymphoma
Phase I
Active Not Recruiting
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
Apr 04, 2019
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Allogene Therapeutics Inc (ALLO) have in its pipeline
ALLO is currently developing the following drugs: Allo-329, Cyclophophamide, Cyclophosphamide, Fludarabine, Cemacabtagene Ansegedleucel, Foresight Clarity™ Iuo Mrd Test, Powered By Phased-Seq™, Cyclophosphamide, Fludarabine, Allo-647, Allo-501A. These drug candidates are in various stages of clinical development as the company works toward FDA approval.